Lento Bio is a preclinical pharmaceutical company developing novel eyedrops to treat presbyopia by directly reversing lens stiffness at the molecular level. Founded in 2022, the company has advanced its lead asset LB-01 from concept through preclinical validation, demonstrating significant restoration of lens flexibility in both animal and human ex vivo models. Lento Bio is currently completing IND-enabling studies in preparation for clinical trials.
Lento Bio is headquartered in Syracuse, NY, where it operates within a biotech incubator alongside strategic partner Ichor Life Sciences. The company’s research and development efforts are supported by collaborations with Florida State University and an experienced network of ophthalmology and pharmaceutical development advisors.
Our mission is to eliminate the need for reading glasses by reversing presbyopia at its source.
Unlike existing pharmacological approaches to presbyopia, which rely on pupil constriction to temporarily improve depth of focus, Lento Bio’s approach targets the underlying cause of lens stiffening — the accumulation of aberrant protein crosslinks that occurs as the lens’s natural protective systems decline with age. By restoring a quality control function the lens has lost, LB-01 has the potential to produce durable improvements in accommodation that persist after treatment cessation.
Proof that we can repair aging damage in the earliest onset and most ubiquitous aging disorder
We are restoring the natural physiology and function of the lens rather than seeking a workaround
Once you remove biomolecular aging damage, the therapeutic effect will last sans extra treatment
Our approach avoids the critical issues associated with miotics (headaches, night-vision loss, etc)
